BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27148840)

  • 1. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.
    Castaman G; Federici AB
    Semin Thromb Hemost; 2016 Jul; 42(5):478-82. PubMed ID: 27148840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
    J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
    Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
    Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
    Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B.
    Nurden P; Gobbi G; Nurden A; Enouf J; Youlyouz-Marfak I; Carubbi C; La Marca S; Punzo M; Baronciani L; De Marco L; Vitale M; Federici AB
    Blood; 2010 Apr; 115(13):2649-56. PubMed ID: 20118404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
    Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
    Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on type 2B von Willebrand disease.
    Mikhail S; Aldin ES; Streiff M; Zeidan A
    Expert Rev Hematol; 2014 Apr; 7(2):217-31. PubMed ID: 24521271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
    Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
    Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies.
    Frontroth JP; Favaloro EJ
    Methods Mol Biol; 2017; 1646():473-494. PubMed ID: 28804849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
    Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
    Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat type 2B von Willebrand disease.
    Kruse-Jarres R; Johnsen JM
    Blood; 2018 Mar; 131(12):1292-1300. PubMed ID: 29378695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
    Shen MC; Lin JS; Lin DS; Hsu SC; Lin B
    Thromb Res; 2003; 112(5-6):291-5. PubMed ID: 15041272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
    Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
    Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.